AOCNP Immunotherapy and Targeted Therapy 3

Question 1

Which immune-related adverse event (irAE) is most commonly associated with anti-PD-1/PD-L1 therapy?

Accepted Answer

Hypothyroidism

Answer

Myocarditis

Answer

Colitis

Answer

Pneumonitis

Question 2

Bispecific T-cell engager (BiTE) blinatumomab works by simultaneously binding which two targets?

Accepted Answer

CD3 on T cells and CD19 on B-cell tumors

Answer

PD-1 and CTLA-4

Answer

HER2 and EGFR

Answer

VEGFR and PDGFR

Question 3

A patient with metastatic colorectal cancer has a KRAS wild-type, RAS/RAF wild-type tumor. Which targeted therapy is most appropriate?

Accepted Answer

Cetuximab or panitumumab (anti-EGFR)

Answer

Bevacizumab monotherapy

Answer

Imatinib

Answer

Vemurafenib

Question 4

Which toxicity is specifically associated with VEGFR/multi-kinase inhibitors (sunitinib, sorafenib) and requires proactive management?

Accepted Answer

Hand-foot skin reaction (palmar-plantar erythrodysesthesia)

Answer

Severe anemia

Answer

Immune-related colitis

Answer

Severe neuropathy

Question 5

Chimeric antigen receptor T-cell (CAR-T) therapy requires T cells to be genetically engineered to express a receptor targeting which antigen in most approved hematologic malignancy indications?

Accepted Answer

CD19 or BCMA

Answer

CD20

Answer

CD3

Answer

PD-L1

Question 6

The ONCO NP is educating a patient beginning osimertinib. Which side effect is most important to monitor and manage proactively?

Accepted Answer

Dermatologic toxicity and QTc prolongation

Answer

Severe cytokine release syndrome

Answer

Severe hemorrhagic cystitis

Answer

Grade 3–4 mucositis